Phase I/II study of erlotinib plus S-1 for patients with previously treated non-small cell lung cancer: Thoracic Oncology Research Group (TORG) 0808/0913

Introduction In preclinical data, the combination therapy with S-1 and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) had a synergistic antitumor effect on non-small cell lung cancer (NSCLC), regardless of the EGFR mutation status. Patients and Methods Patients with previous...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Invest New Drugs
Hoofdauteurs: Nakahara, Yoshiro, Shimokawa, Tsuneo, Misumi, Yuki, Nogami, Naoyuki, Shinkai, Tetsu, Seki, Nobuhiko, Hosomi, Yukio, Hida, Naoya, Okamoto, Hiroaki
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Springer US 2020
Onderwerpen:
Phase II Studies
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7851018/
https://ncbi.nlm.nih.gov/pubmed/32803700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-00985-4
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items